SMi's 9th Annual Orphan Drugs & Rare Diseases Conference

SMi Group 15 - 16 October 2019, London, UK.
The orphan drug market is continuously growing and is expected to reach $176 billion by 2020, with a CGR of 10.5% just for orphan drugs - this is twice the growth rate of the overall prescription drug market (5.3% CGR from 2014-2020). By 2020, orphan drugs are set to account for 19% of global prescription sales.

This is due to the arising interest from pharmaceutical companies for underlying benefits, such as the potential discovery of mechanisms for more common diseases, and also the involvement of many smaller biotechnology start-up companies who are primarily focused on rare diseases.

The 2019 agenda features various key presentations by leading solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders discussing possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.

Benefits of attending

  • HEAR about the success of integrated approaches to develop a robust early access and evidence generation plan with Bionical Emas
  • DISCUSS the intervention of pharmaceutical companies and patient advocates in developing lifelong rare disease treatments with Takeda
  • EXPLORE the current development of strategies aimed to improve patient access to orphan drugs with Genetic Alliance UK
  • GAIN INSIGHT into the various challenges facing orphan drug development with Minoryx Therapeutics

Interactive half-day post-conference workshop

17th October 2019

A deep dive into strategies for accelerating patient access of orphan drugs
Workshop Leader: Workshop Leaders: Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca
Cecile Ollivier, Chief Operating Officer, Aparito

For more information and to register, please visit http://www.orphandrugs.co.uk/wpnWL

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...